For more than a decade researchers have been unleashing a deluge of information about the role of genes in disease, based on automated sequencing of DNA. Genetic tests (Read more...)
San Diego-based BioNano Genomics, which has taken a fundamentally different approach to analyzing the genome, says today it has closed on $53 million in Series C financing (Read more...)
N30 Pharmaceuticals, a Boulder-based pharmaceutical company developing drugs for cystic fibrosis, announced yesterday it has raised a $30 million mezzanine financing round. N30 Pharma will use the (Read more...)
The Fred Hutchinson Cancer Research Center in Seattle has unveiled D. Gary Gilliland as its new president and director. He steps to the helm with a strong tailwind, (Read more...)
Shares of Clovis Oncology dropped 10 percent this morning following the release of interim results for the ongoing trial of the company’s drug for lung cancer patients.
Analysts (Read more...)
The next time Gilead Sciences (NASDAQ: GILD) has a drug ready for an all-important Food and Drug Administration review, it can jump the line.
That’s because Gilead, (Read more...)
Houston biotech firm Bellicum Pharmaceuticals has filed for a $115 million IPO.
The company is developing immunotherapies that allow the suppression or activation of cells administered to patients (Read more...)
Vertex Pharmaceuticals has developed a drug that has changed the way cystic fibrosis is treated for some patients with a specific genetic mutation. And now the non-profit organization (Read more...)
Agios Pharmaceuticals turned heads in April when it showed its first drug prospect might be able to treat a devastating blood cancer, acute myeloid leukemia (AML), in people (Read more...)
There is a major transformational step underway for managing the growing amount of human genomic data. To date, the focus has been on amassing databanks of genomes and (Read more...)
Scientists at The Scripps Research Institute have produced the first 3-D image of how the ZMapp drug developed by San Diego’s Mapp Biopharmaceutical binds to the Ebola (Read more...)
[Corrected 11/17/14, 12:30pm. See below.] If nothing else, the acronym RNAi, which stands for ribonucleic acid interference, should be familiar to biotech observers as something that (Read more...)
Few biotech startups have burst onto the scene like Juno Therapeutics. The Seattle company secured $310 million in private financing in less than a year, budding out of (Read more...)
Hector DeLuca is the embodiment of nearly a century of University of Wisconsin research into Vitamin D, and he’s working to extend that reach for at least another (Read more...)
It’s notoriously tough to develop just about anything that helps patients with glioblastoma, an aggressive brain cancer, live longer. It’s just as hard to develop a vaccine that (Read more...)